ITHACA, N.Y. –– Rheonix Inc., developer of automated molecular diagnostic platforms and consumables, added two new members to its management team. Steve Pemberton joins the company as vice president of marketing and sales, and Bryan Greene was named director of consumable manufacturing. These appointments will help Rheonix manufacture, launch, market and distribute its EncompassMDx™ molecular platform and associated Rheonix CARD® assays.
“I am very excited we have brought Steve and Bryan to Rheonix,” said Tony Eisenhut, president. “The groups they will lead will not only provide our business with the tools we need to grow our products, but will expand our existing focus, which has been on customer needs and manufacturing features necessary for a medical device company to be a valuable part of the clinical ecosystem.”
As vice president of marketing and sales, Pemberton will broaden and execute on the commercialization strategy and guide Rheonix’s new product launches into specific segments of the broad molecular analysis market. He previously held leadership positions at in vitro diagnostics companies Abbott Diagnostics, Ventana Medical Systems and Roche Diagnostics. He holds a bachelor’s degree from Arizona State University.
“Rheonix is uniquely capable of delivering fully automated sample-to-result molecular assays to customers at disruptive price points,” Pemberton said. “My passion for the last 16 years in the industry has been to bring better tools to the hands of laboratorians. I feel my passion and capabilities complement the experienced management team in place at Rheonix and will speed introduction of our products to the market.”
Greene holds a bachelor’s degree from Clarkson University and has worked in manufacturing of biological grade reagents and consumables for nearly a decade. Most recently, he was responsible for design transfer to manufacturing of new products at Life Technologies Corporation.
“Bryan brings to Rheonix the ability to create and grow our manufacturing team, transfer designs to production and reliably produce our CARD cartridges and reagent packs,” Eisenhut said.
Rheonix Inc. is committed to improving standards of care by making molecular diagnostics available to more people, in more places, more often. Rheonix, through experienced leadership and creative vision, has developed the EncompassMDx™ platform, a highly customizable technology with unmatched versatility and affordability. The platform performs fully automated, complex molecular assays in an easy-to-use and economical format on the Rheonix CARD® cartridge. With both the Rheonix CARD® and EncompassMDx™ family of products, Rheonix is well-positioned to penetrate key molecular diagnostic market sectors, from reference labs through point-of-care and everywhere in between.
For more information, visit www.rheonix.com.